1. Home
  2. GBTG vs AKRO Comparison

GBTG vs AKRO Comparison

Compare GBTG & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Global Business Travel Group Inc.

GBTG

Global Business Travel Group Inc.

HOLD

Current Price

$7.94

Market Cap

4.3B

Sector

Technology

ML Signal

HOLD

Logo Akero Therapeutics Inc.

AKRO

Akero Therapeutics Inc.

HOLD

Current Price

$54.54

Market Cap

4.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GBTG
AKRO
Founded
2014
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.3B
4.5B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
GBTG
AKRO
Price
$7.94
$54.54
Analyst Decision
Strong Buy
Buy
Analyst Count
4
10
Target Price
$10.25
$73.56
AVG Volume (30 Days)
1.6M
1.7M
Earning Date
11-10-2025
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.01
N/A
Revenue
$2,517,000,000.00
N/A
Revenue This Year
$14.24
N/A
Revenue Next Year
$19.87
N/A
P/E Ratio
$414.63
N/A
Revenue Growth
5.71
N/A
52 Week Low
$5.78
$21.34
52 Week High
$9.57
$58.40

Technical Indicators

Market Signals
Indicator
GBTG
AKRO
Relative Strength Index (RSI) 57.18 66.54
Support Level $7.85 $54.22
Resistance Level $8.06 $54.70
Average True Range (ATR) 0.23 0.14
MACD 0.09 -0.11
Stochastic Oscillator 88.84 64.18

Price Performance

Historical Comparison
GBTG
AKRO

About GBTG Global Business Travel Group Inc.

Global Business Travel Group Inc operates as a business-to-business travel platform. It is engaged in providing software and services to manage travel, expenses, and meetings and events for companies of all sizes. The company is engaged in building the marketplace in B2B travel to deliver unrivaled choice, value, and experiences. It also provides business travel solutions, simplified travel management, and business consulting services. Further, The company generates revenue in two ways that involves fees and other revenues relating to processing and servicing travel transactions received from clients and travel suppliers and revenues for the provision of products and professional services not directly related to transactions received from clients, travel suppliers and Network Partners.

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

Share on Social Networks: